Sanofi And Regulus Sign RNA Pact | June 28, 2010 Issue - Vol. 88 Issue 26 | Chemical & Engineering News
Volume 88 Issue 26 | p. 23 | Concentrates
Issue Date: June 28, 2010

Sanofi And Regulus Sign RNA Pact

Department: Business
Keywords: collaboration, drug development, microRNAs

Regulus Therapeutics will work with Sanofi-Aventis to develop drugs based on microRNAs, a class of small noncoding RNAs that regulate gene expression. Sanofi will pay $25 million up front and make a $10 million investment in the company in the future. All told, Regulus could receive up to $750 million in fees, R&D funding, and potential milestone payments. The partners will work on four initial micro­RNA targets, and Sanofi has the option to develop others. Isis Pharmaceuticals and Alnylam Pharmaceuticals are joint owners of Regulus.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment